Neuland Laboratories' Stock Sees -6.0% Decline, Underperforms Sector and Sensex

Neuland Laboratories, a midcap pharmaceutical company, has seen a decline of -6.0% in its stock price on November 11, 2024. According to MarketsMOJO, the stock has been given a 'Hold' call. The stock has underperformed the sector by -3.8% and has been on a consecutive fall for the last 4 days, with a total decline of -16.57% in this period.

On November 11, the stock touched an intraday low of Rs 13211.05, showing a decrease of -4.27%. However, the stock's moving averages are still higher than the 100 day and 200 day moving averages, but lower than the 5 day, 20 day, and 50 day moving averages.

In comparison to the Sensex performance, Neuland Laboratories' stock has shown a decline of -6.16% in the last 1 day, while the Sensex has only declined by -0.12%. Similarly, in the last 1 month, the stock has underperformed the Sensex by -9.24%, with the Sensex showing a decline of -2.44%.

Despite the recent decline in stock price, Neuland Laboratories remains a midcap company in the pharmaceutical industry. As a neutral and informative article, it is important to note that this article does not mention any future potential, investor interest, or expert opinions. The information provided is based on facts and data from MarketsMOJO.